Physician profile
Sharon Nelson
NPI 1629044417
$4,308.57
in general payments reported to CMS, 2019-2025
30 companies · $440 in 2025
The $440 reported for 2025 was more than what 77% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $475 · 2020: $903 · 2021: $819 · 2022: $683 · 2023: $576 · 2024: $414 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,428.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,154.81 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $438.28 | 2021-2025 | |
| Therapeuticsmd, INC. | $411.31 | 2019-2022 | |
| Astellas Pharma US INC | $198.53 | 2023-2024 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $190.97 | 2019-2025 | Slynd |
| Avion Pharmaceuticals | $186.38 | 2020-2022 | |
| Pfizer INC. | $186.19 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $157.37 | 2019-2025 | Gardasil 9, Gardasil |
| Exact Sciences Corporation | $156.11 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $144.55 | 2019-2020 | |
| Evofem Biosciences, INC. | $121.90 | 2020-2023 | Phexxi |
| Sage Therapeutics, LLC | $114.08 | 2024-2025 | Zurzuvae |
| Lupin INC. | $107.95 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $98.26 | 2019-2024 | |
| Myovant Sciences INC. | $76.08 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $65.91 | 2019-2020 | |
| Hologic Sales and Service, LLC | $60.16 | 2019-2021 | |
| Coopersurgical, INC. | $56.14 | 2019-2022 | |
| Agile Therapeutics, INC. | $52.62 | 2021-2024 | Twirla |
| Scynexis, INC. | $50.60 | 2022 | |
| Vertical Pharmaceuticals, LLC | $49.80 | 2019 | |
| Millicent US INC | $43.79 | 2025 | Intrarosa, Femlyv, Femring |
| Organon LLC | $40.21 | 2021-2024 | |
| Zyla Life Sciences, INC. | $37.69 | 2020 | |
| Ascend Therapeutics US, LLC | $29.84 | 2021 | |
| Supernus Pharmaceuticals, INC. | $26.75 | 2025 | Qelbree |
| Mycovia Pharmaceuticals, INC. | $14.79 | 2023 | Vivjoa |
| Sumitomo Pharma America, INC. | $13.35 | 2023 | Myfembree |
| Boston Scientific Corporation | $13.26 | 2019 | |
| Duchesnay USA Incorporated | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.